ERa inhibitors
1 abstract
Abstract
Kinome reprogramming as a therapeutic opportunity in ESR1 fusion driven breast cancer but not in gynecologic cancers.Org: Caris Life Sciences Research and Development, Tempero Bio, Azidus Brasil, Caris Life Sciences, Phoenix Tissue Repair,